Stage-dependent performance and molecular subtype-specific relapse patterns on same-session [18F]FDG PET/contrast-enhanced CT in breast cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8189-8202
DOI: 10.1007/s00259-026-08077-w ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 07.08.2026. Verfasst von Agostino Chiaravalloti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Viale Montpellier 1, Rome, 00133, Italy. agostino.chiaravalloti@uniroma2.it. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Breast Neoplasms, Positron Emission Tomography Computed Tomography, Contrast Media. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Roma Tor Vergata.
Abstract (Originalsprache)
Purpose
To evaluate stage-dependent performance of same-session [18F]FDG PET/contrast-enhanced CT (PET/ceCT) for initial breast cancer staging and PET/ceCT-detected relapse patterns during follow-up.
Methods
This retrospective single-centre study included a primary staging cohort with one index PET/ceCT per patient and a longitudinal cohort of follow-up/restaging examinations. PET/ceCT-derived endpoints were assessed against clinically adjudicated reference standards established through multidisciplinary team review, pathology when available and follow-up imaging. SUVmax and ceCT lesion diameter were analysed as exploratory biomarkers.
Results
The staging cohort included 116 patients. Baseline stage was evaluable in 106 patients: 65 had cN-positive disease, 9 had cT3-4 cN0 disease and 32 had cT1-2 cN0 disease. Overall nodal staging performance showed sensitivity 64.8%, specificity 88.9%, PPV 92.0%, NPV 56.1% and accuracy 72.9%. In cT3-4 and/or cN-positive disease, PET-positive nodal findings had a PPV of 100%. Baseline M-stage assessment was limited by the low number of clinically confirmed M1 cases. SUVmax correlated with Ki-67 (rho = 0.322, p = 0.003, q = 0.022). The longitudinal cohort included 176 patients and 429 examinations. In 311 adjudicated examinations, restaging performance for disease progression showed sensitivity 100%, specificity 93.5%, PPV 97.3%, NPV 100% and accuracy 98.1%. First confirmed relapse was multiorgan/multisystem in 48/82 patients and visceral-only in 15/82; visceral conversion occurred in 5/16 patients with initial bone-only or nodal/locoregional relapse.
Conclusion
Same-session [18F]FDG PET/ceCT showed greatest baseline utility in higher-risk breast cancer and was useful for longitudinal characterization of relapse phenotype and metastatic evolution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Viale Montpellier 1, Rome, 00133, Italy. agostino.chiaravalloti@uniroma2.it.
- IRCCS Neuromed, Via Atinense 18, Pozzilli, 86077, IS, Italy. agostino.chiaravalloti@uniroma2.it.
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Viale Montpellier 1, Rome, 00133, Italy.
- Medical Oncology Unit, Fondazione PTV Policlinico Tor Vergata, Viale Oxford 81, Rome, 00133, Italy.
- Department of Electronic Engineering and Information Science, University of Science and Technology of China, Hefei, Anhui, China.
- Department of Biomedical Engineering, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Förderung
- Università degli Studi di Roma Tor Vergata
Zitieren
APA
Chiaravalloti, A., Samarxhiu, S., Portarena, I., Flaminio, V., D'Ascenzo, N., Schillaci, O., & Vanni, G. (2026). Stage-dependent performance and molecular subtype-specific relapse patterns on same-session [18F]FDG PET/contrast-enhanced CT in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8189-8202. https://doi.org/10.1007/s00259-026-08077-w
Vancouver
Chiaravalloti A, Samarxhiu S, Portarena I, Flaminio V, D'Ascenzo N, Schillaci O, et al. Stage-dependent performance and molecular subtype-specific relapse patterns on same-session [18F]FDG PET/contrast-enhanced CT in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8189-8202. doi:10.1007/s00259-026-08077-w
BibTeX
@article{Chiaravalloti2026,
author = {Chiaravalloti, Agostino and Samarxhiu, Shyqyri and Portarena, Ilaria and Flaminio, Valeria and D'Ascenzo, Nicola and Schillaci, Orazio and Vanni, Gianluca},
title = {Stage-dependent performance and molecular subtype-specific relapse patterns on same-session [18F]FDG PET/contrast-enhanced CT in breast cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8189--8202},
doi = {10.1007/s00259-026-08077-w}
}
EUVIMED